Best Ophthalmology podcasts — Eye and vision research (Updated August 2017; image)
Related podcasts: Science Retina Cataract Medicine Health and Well-Being Glaucoma Cornea Business Eyes Optometry Spine Medical Brain Health Tech Education US Government Duke Health Diabetes And Endocrinology Cme/ce  
public [subscription 1120]
show episodes
Medscape Ophthalmology Podcast
Latest medical news and features from Medscape Ophthalmology
As Seen From Here
the Ophthalmology podcast
OIS Podcast
Welcome to the Ophthalmology Innovation Podcast where you get candid conversations with the leaders & drivers of ophthalmic innovation.
Loading …
show series
Guests: Soon Phaik Chee, MD Associate Professor Singapore National Eye Centre Singapore Mingguang He, MD, PhD Professor of Ophthalmic Epidemiology University of Melbourne and Centre for Eye Research Australia Director of WHO Collaborating Centre for Prevention of Blindness (Australia) Melbourne, Australia…
OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS president, shares details on his next undertaking – finding a way to measure the value of vision protection. Meanwhile, Dr. Pollack highlights one of his ...…
Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the globa ...…
OIS Co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, managing director, Clarus Funds, walks us through the agenda of Thursday’s OIS@ASRS. What areas of retina will dominate the headlines for the next 12 months?
Dr Christopher Rapuano sorts through the updated recommendations for dry eye provided in the recently published report of the Tear Film & Ocular Surface Society International Dry Eye Workshop II.
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?…
Guest: Laura M. Periman, MD Seattle, WA
Join in as two ophthalmologists have an in-depth discussion about vancomycin-associated hemorrhagic occlusive retinal vasculitis, including its diagnosis, treatment, and prognosis.
In two recent interviews, Elizabeth Yeu, MD, Virginia Eye Consultants, and Richard Lewis, MD, Sacramento Eye Consultants share how innovation is changing how they treat patients. Reimbursement, marketing and the future of new tech also are discussed.
In this OIS Podcast, David Alpern, partner at Varsity Healthcare Partners, and Brent Wilde, president of Minnesota Eye Consultants, offer complimentary perspectives on Private Equity’s impact on ophthalmology practices.
Guest: Laura M. Periman, MD Seattle, WA
Jerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building a broad pipeline to treat eye disease including dry eye and ocular pain. In this interview he reviews several acquisitions and partnerships the company has made over the past 24 months.…
Laurent Attias, head, strategy, BD&L and M&A, reports on progress on Alcon’s project with Google and its advancing glaucoma portfolio. Attias says Alcon is “open for business” and continuing to advance innovative ideas in ophthalmology.
Guests: Boris Malyugin, MD, PhD Professor of Ophthalmology Department of Cataract & Implant Surgery Deputy Director General S.Fyodorov Eye Microsurgery State Institution Moscow, Russia Adi Abulafia, MD Acting Deputy Head of Ophthalmology Department Assaf HaRofeh Medical Center Tzrifin, Israe
After capturing lighting in a bottle with Oculeve, Ali Behbahani, MD, partner of New Enterprise Associates, recalls the experience with the Dry Eye start-up and lays out his plans for investing in future ophthalmology start-ups.
Max G. Ostermeier, MBA, co-founder and general manager of Implandata Ophthalmic Products GmbH, charts a course for the company after securing CE mark for its EYEMATE eye pressure measurement system for continuous measurement of IOL in patients with glaucoma.
Physicians from all over the country tell Medscape about their experiences with the ACA. What's your take?
Guest: Priya Narang, MS Narang Eye Care & Laser Centre Ahmedabad, India
Mynosys Cellular Devices CEO and president John Hendrick lays out his company’s plan to roll out Zepto in the US. The firm has reported strong demand in OUS markets, and Hendrick anticipates it will upend the capsulotomy market.
Eric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and it enables me to spend more time talking to the patients about therapies,” Dr. Donnenfeld says. He also praises Shire and Allergan for their effective marketing.…
Guests: Arsham Sheybani, MD Assistant Professor Ophthalmology and Visual Sciences Washington University School of Medicine St Louis, MO Devesh Varma, MD Assistant Professor Department of Ophthalmology & Vision Sciences University of Toronto School of Medicine Toronto, ON, Canada
In this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says new hires brought on to prepare for likely commercial sale of Rhopressa bring new life and energy into a company hitting its stride. He also provides to OIS@ASCRS an update on the firm’s glaucoma pipeline.
Ludwin Monz, PhD, President and CEO of Carl Zeiss Meditec explains why the ophthalmology leader brought in new senior leadership. He also reviews the company’s recent product approvals and gives an assessment of the “amazing possibilities” within diagnostics.
Now that Shire’s Xiidra claims a 20% market share, find out how it’s impacting the practice. Alice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to explain how Shire, TrueTear, and other advances are impacting her Dry Eye patients.
Guest: Greg Moloney, MD Mosman, Australia
LensGen CEO Ram Rao discusses his company’s $21 million Series A and the increased interest in presbyopia.
Guests: Ehud Assia, MD Professor of Ophthalmology Tel-Aviv University Medical School Tel-Aviv, Israel Jeffrey Whitman, MD   Dallas, TX
Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following a successful OIS@ASCRS.
Gil Kliman, managing director at InterWest Partners, reviews his role at the upcoming OIS@ASCRS, including an overview of anterior segment innovation and a discussion on lower myopia.
Longtime eye bank executive David Korroch, chief executive officer, Lions Medical Eye Bank, explains how eye banks have worked hard to meet – and even exceed – the demand for donated tissue. Korroch is the winner of this year’s Leonard Heise Award.
As Seen From Here
Guest: Jodhbir Mehta, MD Associate Professor, Head of Cornea External Disease, Senior Consultant in Refractive Surgery Singapore National Eye Centre Singapore
Mark S. Blumenkranz, MD, H. J. Smead Professor of Ophthalmology, Emeritus, delivers his State of Innovation address. You can guess what his assessment is, but we’ll give you a hint. It involves cool lasers.
Guests: Garry Condon, M.D. Pittsburgh, PA Robert J. Cionni, M.D. Salt Lake City, UT
OIS Co-Chair William J. Link, PhD walks us through OIS@ASCRS’ May 4 agenda, which takes place in LA. Link also explains why he Andy Corley and Richard Lindstrom, MD, formed Flying L Partners. Hear about the firm’s most recent investment.
From his clinic in South Dakota, Vance Thompson has served as an investigator in over 60 clinical trials. Thompson taps this experience to shed some light on new innovations being brought forth by Zeiss, Avedro, Allergan, and RxSight. He also offers a few insights on new advances coming down the pike.…
In 2015, three patients who had a stem cell mixture injected in their eyes were severely injured. To try to prevent this from happening again, their treating physicians reached out to the FDA and clinical societies, and ultimately they wrote a paper for the New England Journal of Medicine to warn others about the dangers of these so-called trea ...…
Guest: Guy J. Ben Simon, MD Professor of Ophthalmology Sackler Faculty of Medicine Tel Aviv University Tel Aviv, Israel
Post-concussion, oculomotor and binocular visual issues are more likely to disrupt kids' schooling, says Dr Christina Master.
Newly appointed President and CEO Nancy Lurker explains why she took over as CEO and President at pSivida and gives details on the company’s early clinical testing results in the recurrence of uveitis. Lurker hits upon filing for regulatory approval filings, building a sale team and operating a drug company at a time of political uncertainty.…
Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma.
Last month, Minnesota Eye Consultants announced it was working with private equity investor Waud Capital to create an entity that could build a national eye care provider. In part two of our interview with MEC founder Richard Lindstrom, MD, we discuss the impact similar consolidations could have on the sector.…
Guests: Jodhbir Mehta, MD Associate Professor, Head of Cornea External Disease, Senior Consultant in Refractive Surgery Singapore National Eye Centre Singapore Alvin L. Young, MD Chief of Service, Department of Ophthalmology & Visual Sciences Prince of Wales and Alice Ho Miu Ling Nethersole Hospitals The Chinese University of Hong Kong Hong Kong…
Consolidation is coming to ophthalmology. Last month, Minnesota Eye Consultants agreed to partner with a private equity group to expand beyond the Twin Cities. In the first of a two-part podcast, founder Richard Lindstrom, MD, explains why the deal was done.
Cedric Francois, co-founder, CEO, and president of Apellis delivers an update on his start-up’s promising complement therapies. He also shares why he joined other Biotech CEOs and VCs in speaking against the proposed immigration restrictions.
Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia
On February 28, the National Eye Institute will host a webinar to introduce its 3D Retina Organoid Challenge. Its objective is simple: use $1 million in prize money to encourage researchers from multiple disciplines to create a critical tool for retinal research. The NEI’s Jessica Mazerik and Steve Becker share the details, which can also be fo ...…
Ophthalmology CEO turned VC Abbie Celniker, now a partner at Third Rock Ventures, discusses her role at the firm and reveals how it will invest its new $616 million fund.
Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia
With Novartis’ acquisition of Encore Vision setting the standard, CEO Jim McCollum and CSO Jerry Horn, MD, tell the tale of Presbyopia Therapies, a small start-up that is working to develop “lifestyle” eye drops that can help presbyopes read without assistance.
Series preference

Google login Twitter login Classic login